Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
38.80
-0.27 (-0.69%)
At close: Aug 1, 2025, 4:00 PM
38.99
+0.19 (0.49%)
After-hours: Aug 1, 2025, 7:45 PM EDT

Company Description

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).

The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.

In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.

The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3.

The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Legend Biotech Corporation
Legend Biotech logo
CountryUnited States
Founded2014
IPO DateJun 5, 2020
IndustryBiotechnology
SectorHealthcare
Employees2,609
CEOYing Huang

Contact Details

Address:
2101 Cottontail Lane
Somerset, New Jersey 08873
United States
Phone737 317 5050
Websitelegendbiotech.com

Stock Details

Ticker SymbolLEGN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$23.00
CIK Code0001801198
CUSIP Number52490G102
ISIN NumberUS52490G1022
SIC Code2834

Key Executives

NamePosition
Dr. Ying Huang Ph.D.Chief Executive Officer and Director
Jessie Yeung M.B.A.Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Shu WuSenior Vice President of Global Operations and GM of Legend China
Caroline LeCates PaulAssociate Director of Investor Relations
James Pepin J.D.General Counsel
Tim RobertsGlobal Compliance Officer
Elaine QianVice President and Global Head of Human Resources
Dr. Guowei Fang Ph.D.President of Research and Development
Dr. Mythili Koneru M.D., Ph.D.Chief Medical Officer
Birk VanderweeenSenior Vice President of Global Manufacturing and Supply

Latest SEC Filings

DateTypeTitle
Jul 23, 2025144Filing
Jul 23, 2025144Filing
Jul 16, 20256-KReport of foreign issuer
Jun 30, 20256-KReport of foreign issuer
Jun 26, 2025144Filing
Jun 25, 2025144Filing
Jun 24, 2025144Filing
Jun 24, 2025144Filing
Jun 12, 20256-KReport of foreign issuer
Jun 6, 20256-KReport of foreign issuer